Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 14 |
| List of Tables | 13 | 2 |
| List of Figures | 15 | 1 |
| Introduction | 16 | 1 |
| Global Markets Direct Report Coverage | 16 | 1 |
| Duchenne Muscular Dystrophy Overview | 17 | 1 |
| Therapeutics Development | 18 | 2 |
| Pipeline Products for Duchenne Muscular Dystrophy Overview | 18 | 1 |
| Pipeline Products for Duchenne Muscular Dystrophy Comparative Analysis | 19 | 1 |
| Duchenne Muscular Dystrophy Therapeutics under Development by Companies | 20 | 5 |
| Duchenne Muscular Dystrophy Therapeutics under Investigation by Universities/Institutes | 25 | 1 |
| Duchenne Muscular Dystrophy Pipeline Products Glance | 26 | 4 |
| Late Stage Products | 26 | 1 |
| Clinical Stage Products | 27 | 1 |
| Early Stage Products | 28 | 1 |
| Unknown Stage Products | 29 | 1 |
| Duchenne Muscular Dystrophy Products under Development by Companies | 30 | 5 |
| Duchenne Muscular Dystrophy Products under Investigation by Universities/Institutes | 35 | 1 |
| Duchenne Muscular Dystrophy Companies Involved in Therapeutics Development | 36 | 41 |
| Acceleron Pharma, Inc. | 36 | 1 |
| Anagenesis Biotechnology | 37 | 1 |
| Asklepios BioPharmaceutical, Inc. | 38 | 1 |
| BioMarin Pharmaceutical Inc. | 39 | 1 |
| Bristol-Myers Squibb Company | 40 | 1 |
| Capricor Therapeutics, Inc. | 41 | 1 |
| Catabasis Pharmaceuticals, Inc. | 42 | 1 |
| Daiichi Sankyo Company, Limited | 43 | 1 |
| Debiopharm International SA | 44 | 1 |
| Editas Medicine, Inc. | 45 | 1 |
| EryDel SPA | 46 | 1 |
| FibroGen, Inc. | 47 | 1 |
| Galapagos NV | 48 | 1 |
| Genethon | 49 | 1 |
| GTx, Inc. | 50 | 1 |
| GW Pharmaceuticals Plc | 51 | 1 |
| Idera Pharmaceuticals, Inc. | 52 | 1 |
| Italfarmaco S.p.A. | 53 | 1 |
| La Jolla Pharmaceutical Company | 54 | 1 |
| Lexicon Pharmaceuticals, Inc. | 55 | 1 |
| Marathon Pharmaceuticals, LLC | 56 | 1 |
| Marina Biotech, Inc. | 57 | 1 |
| Merck KGaA | 58 | 1 |
| Milo Biotechnology LLC | 59 | 1 |
| Mitochon Pharmaceuticals, Inc. | 60 | 1 |
| MyoTherix Inc. | 61 | 1 |
| NicOx S.A. | 62 | 1 |
| Nippon Shinyaku Co., Ltd. | 63 | 1 |
| Nobelpharma Co., Ltd. | 64 | 1 |
| Pfizer Inc. | 65 | 1 |
| Pluristem Therapeutics Inc. | 66 | 1 |
| Prothelia, Inc. | 67 | 1 |
| PTC Therapeutics, Inc. | 68 | 1 |
| RASRx, LLC | 69 | 1 |
| ReveraGen BioPharma, Inc. | 70 | 1 |
| Santhera Pharmaceuticals Holding AG | 71 | 1 |
| Sarepta Therapeutics, Inc. | 72 | 1 |
| Summit Therapeutics Plc | 73 | 1 |
| Taiho Pharmaceutical Co., Ltd. | 74 | 1 |
| WAVE Life Sciences Ltd. | 75 | 1 |
| Zambon Company S.p.A. | 76 | 1 |
| Duchenne Muscular Dystrophy Therapeutics Assessment | 77 | 11 |
| Assessment by Monotherapy Products | 77 | 1 |
| Assessment by Target | 78 | 3 |
| Assessment by Mechanism of Action | 81 | 3 |
| Assessment by Route of Administration | 84 | 2 |
| Assessment by Molecule Type | 86 | 2 |
| Drug Profiles | 88 | 178 |
| 4-P001 Drug Profile | 88 | 1 |
| AAV1-Foliistatin Drug Profile | 89 | 2 |
| ACE-083 Drug Profile | 91 | 2 |
| alisporivir Drug Profile | 93 | 3 |
| Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile | 96 | 1 |
| Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile | 97 | 1 |
| Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD Drug Profile | 98 | 1 |
| Antisense Oligonucleotides to Inhibit ACVR2B for Duchenne Muscular Dystrophy Drug Profile | 99 | 1 |
| Antisense RNAi Oligonucleotides for Duchenne Muscular Dystrophy Drug Profile | 100 | 1 |
| Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders Drug Profile | 101 | 1 |
| arbekacin Drug Profile | 102 | 1 |
| ARM-210 Drug Profile | 103 | 2 |
| AT-300 Drug Profile | 105 | 2 |
| ataluren Drug Profile | 107 | 8 |
| Biostrophin Drug Profile | 115 | 1 |
| BMBD-001 Drug Profile | 116 | 1 |
| BMS-986089 Drug Profile | 117 | 1 |
| CAP-1002 Drug Profile | 118 | 5 |
| CAP-2003 Drug Profile | 123 | 1 |
| CAT-1004 Drug Profile | 124 | 4 |
| DA-4210 Drug Profile | 128 | 1 |
| deflazacort Drug Profile | 129 | 2 |
| dexamethasone sodium phosphate Drug Profile | 131 | 2 |
| domagrozumab Drug Profile | 133 | 2 |
| Drug for Duchenne Muscular Dystrophy Drug Profile | 135 | 1 |
| Drugs for Duchenne Muscular Dystrophy Drug Profile | 136 | 1 |
| DS-5141 Drug Profile | 137 | 1 |
| DT-200 Drug Profile | 138 | 1 |
| enobosarm Drug Profile | 139 | 7 |
| eteplirsen Drug Profile | 146 | 11 |
| ezutromid Drug Profile | 157 | 6 |
| Gene Therapy for Duchenne Muscular Dystrophy Drug Profile | 163 | 1 |
| Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies Drug Profile | 164 | 1 |
| Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile | 165 | 1 |
| Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile | 166 | 1 |
| Gene Therapy to Activate Utrophin for Duchenne Muscular Dystrophy Drug Profile | 167 | 1 |
| givinostat Drug Profile | 168 | 2 |
| Gtx-027 Drug Profile | 170 | 1 |
| IB-DMD Drug Profile | 171 | 1 |
| idebenone Drug Profile | 172 | 8 |
| IMO-8400 Drug Profile | 180 | 6 |
| LJPC-30Sa Drug Profile | 186 | 1 |
| LJPC-30Sb Drug Profile | 187 | 1 |
| LX-2931 Drug Profile | 188 | 2 |
| MG-53 Drug Profile | 190 | 2 |
| MP-101 Drug Profile | 192 | 1 |
| Myomir Drug Profile | 193 | 1 |
| naproxcinod Drug Profile | 194 | 3 |
| NS-065 Drug Profile | 197 | 1 |
| Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile | 198 | 1 |
| Oligonucleotides 1 to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile | 199 | 1 |
| Oligonucleotides 2 to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile | 200 | 1 |
| Oligonucleotides 3 to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile | 201 | 1 |
| OSX-200 Drug Profile | 202 | 1 |
| pamrevlumab Drug Profile | 203 | 6 |
| PLX-PAD Drug Profile | 209 | 9 |
| poloxamer Drug Profile | 218 | 2 |
| PRO-052 Drug Profile | 220 | 2 |
| PRO-055 Drug Profile | 222 | 2 |
| PRT-01 Drug Profile | 224 | 2 |
| Recombinant Protein for Muscular Dystrophy Drug Profile | 226 | 1 |
| Recombinant Protein to Activate Utrophin for Muscular Dystrophies Drug Profile | 227 | 1 |
| Recombinant Proteins for Duchenne Muscular Dystrophy Drug Profile | 228 | 1 |
| rimeporide Drug Profile | 229 | 1 |
| RTC-13 Drug Profile | 230 | 2 |
| SB-001 Drug Profile | 232 | 1 |
| SB-002 Drug Profile | 233 | 1 |
| SGT-001 Drug Profile | 234 | 1 |
| Small Molecule to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile | 235 | 1 |
| Small Molecules for Duchenne Muscular Dystrophy Drug Profile | 236 | 1 |
| Small Molecules for Duchenne Muscular Dystrophy Drug Profile | 237 | 1 |
| Small Molecules to Activate Utrophin for Duchenne Muscular Dystrophy Drug Profile | 238 | 1 |
| Small Molecules to Agonize Cannabinoid Receptor for Duchenne Muscular Dystrophy Drug Profile | 239 | 1 |
| SMT-022357 Drug Profile | 240 | 2 |
| SRP-4008 Drug Profile | 242 | 1 |
| SRP-4044 Drug Profile | 243 | 1 |
| SRP-4045 Drug Profile | 244 | 1 |
| SRP-4050 Drug Profile | 245 | 1 |
| SRP-4052 Drug Profile | 246 | 1 |
| SRP-4053 Drug Profile | 247 | 1 |
| SRP-4055 Drug Profile | 248 | 1 |
| Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile | 249 | 2 |
| Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile | 251 | 1 |
| Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy Drug Profile | 252 | 1 |
| Stryka-516 Drug Profile | 253 | 1 |
| Stryka-969 Drug Profile | 254 | 1 |
| StrykaPro-1 Drug Profile | 255 | 1 |
| Synthetic Peptides for Duchene Muscle Dystrophy Drug Profile | 256 | 1 |
| TAS-205 Drug Profile | 257 | 1 |
| TVN-102 Drug Profile | 258 | 1 |
| TXA-127 Drug Profile | 259 | 4 |
| vamorolone Drug Profile | 263 | 2 |
| ZP-049 Drug Profile | 265 | 1 |
| Duchenne Muscular Dystrophy Dormant Projects | 266 | 4 |
| Duchenne Muscular Dystrophy Discontinued Products | 270 | 1 |
| Duchenne Muscular Dystrophy Product Development Milestones | 271 | 11 |
| Featured News &Press Releases | 271 | 1 |
| Jul 25, 2016: PTC Therapeutics Provides Regulatory Update on Translarna (ataluren) | 271 | 1 |
| Jul 20, 2016: NICE publishes final guidance recommending ataluren for children with Duchenne muscular dystrophy | 271 | 2 |
| Jul 14, 2016: Santhera Updates on U.S. Regulatory Filing for Raxone (idebenone) in Duchenne Muscular Dystrophy | 273 | 1 |
| Jul 07, 2016: NHS England Enables Access to Translarna (ataluren) For Patients with Nonsense Mutation Duchenne Muscular Dystrophy | 274 | 1 |
| Jul 07, 2016: Catabasis Pharmaceuticals Announces the Initiation of an Open-Label Extension for the MoveDMD Trial Studying Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy | 274 | 1 |
| Jun 22, 2016: Pluristem Reports Data Showing PLX-PAD Cells Effective in Treating Duchenne Muscular Dystrophy | 275 | 1 |
| Jun 21, 2016: Santhera Marketing Authorization Application for Raxone in Duchenne Muscular Dystrophy (DMD) Validated by the European Medicines Agency | 276 | 1 |
| Jun 20, 2016: Catabasis Pharmaceuticals to Present Edasalonexent (CAT-1004), an Oral Agent Targeting NF-kB: MoveDMDSM Trial in Duchenne Muscular Dystrophy at the 2016 PPMD Annual Connect Conference | 277 | 1 |
| Jun 17, 2016: First Patient Enrolled in Summit s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD | 277 | 1 |
| Jun 14, 2016: CureDuchenne and Catabasis Pharmaceuticals to Host a Webinar to Review Information on Edasalonexent (CAT-1004) and the MoveDMD Trial on June 22, 2016 | 278 | 1 |
| Jun 14, 2016: Marathon Pharmaceuticals Announces Submission of Deflazacort New Drug Application to the FDA | 278 | 1 |
| Jun 08, 2016: Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on MoveDMDSM: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy | 279 | 1 |
| Jun 06, 2016: Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA | 279 | 1 |
| May 31, 2016: Santhera Files Marketing Authorization Application in the European Union for Raxone for the Treatment of Duchenne Muscular Dystrophy | 280 | 1 |
| May 25, 2016: Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug Application By The PDUFA Date | 281 | 1 |
| Appendix | 282 | 2 |
| Methodology | 282 | 1 |
| Coverage | 282 | 1 |
| Secondary Research | 282 | 1 |
| Primary Research | 282 | 1 |
| Expert Panel Validation | 282 | 1 |
| Contact Us | 282 | 1 |
| Disclaimer | 283 | 1 |